Does intravenous immunoglobulin therapy in Guillain-Barré syndrome patients interfere with serological Zika detection?
- 1 June 2019
- journal article
- letter
- Published by Elsevier BV in Autoimmunity Reviews
- Vol. 18 (6), 632-633
- https://doi.org/10.1016/j.autrev.2019.01.004
Abstract
No abstract availableFunding Information
- Institut National de la Santé et de la Recherche Médicale
- Sorbonne Université
- Université Paris Descartes
- Integrative Biology of Emerging Infectious Diseases (ANR-10-LABX-62-IBEID)
- CEFIPRA (5203-3, 4803-1)
This publication has 19 references indexed in Scilit:
- Efficacy and patient satisfaction in the use of subcutaneous immunoglobulin immunotherapy for the treatment of auto-immune neuromuscular diseasesAutoimmunity Reviews, 2018
- Intravenous Immunoglobulins as a new opportunity to treat discoid lupus erythematosusAutoimmunity Reviews, 2018
- Zika virus and autoimmunity. One-step forwardAutoimmunity Reviews, 2017
- Autoimmunity in Guillain-Barré syndrome associated with Zika virus infection and beyondAutoimmunity Reviews, 2017
- Guillain–Barré syndromeAutoimmunity Reviews, 2017
- Guillain–Barré Syndrome Associated with Zika Virus Infection in ColombiaThe New England Journal of Medicine, 2016
- Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control studyThe Lancet, 2016
- Intravenous immunoglobulin as clinical immune-modulating therapyCMAJ : Canadian Medical Association Journal, 2015
- Intravenous Immune Globulin in Autoimmune and Inflammatory DiseasesThe New England Journal of Medicine, 2012
- Clinical features, pathogenesis, and treatment of Guillain-Barré syndromeThe Lancet Neurology, 2008